Abstract
Nitrogen metabolism in humans, as ureotelic organisms, involves reciprocal implications on mitochondrial function and redox homeostasis. The clinical use of valproic acid (VPA), a lysine deacetylase inhibitor, is potentially associated with undesired hyperammonemic encephalopathy (VHE). Our studies focused on: (i) mitochondrial processes conditioning acetyl-CoA production and (ii) Urea cycle (UC) modulating enzymes [1]. To understand if the acute VPA induced depleting effect on NAD homeostasis[2] correlates with sirtuin activity, we evaluated the mitochondrial protein acetylome by immunobloting. To investigate the hypothesis that CPS1 and OTC activities (SIRT5/3 targets) would be altered in vivo, Wistar rats were exposed to the epigenetic modulator VPA. Profiling liver UC and krebs cycles intermediates using targeted mass spectrometry-based methods enabled to characterize specific mitochondrial enzymes function. CPS1 and OTC activity were found to be significantly decreased at the onset of therapy and after repeated drug dosing, respectively. Results account to elucidate preventive strategies for VHE and to gain insights on signaling metabolites-driven adaptations in liver cells and mitonuclear processes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.